Get the latest news, insights, and market updates on PLX (Protalix BioTherapeutics, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Protalix BioTherapeutics (PLX): Evaluating Valuation After EMA Setback on Elfabrio Dosing Regimen
Shares of Protalix BioTherapeutics (PLX) dropped after the European Medicines Agency’s Committee for Medicinal Products for Human Use issued a negative opinion on a proposed less frequent dosing schedule for Elfabrio, its Fabry disease therapy. See our latest analysis for Protalix BioTherapeutics. PLX’s share price tumbled 22.5% in a single day following the EMA setback, wiping out much of the recent momentum that had propelled a 28% gain over the last 90 days. Still, despite recent... Oct 18, 2025 - $PLX
Protalix BioTherapeutics, Inc. (PLX) Gains Investor Confidence With Major Stake Increase
Protalix BioTherapeutics, Inc. (NYSEAMERICAN:PLX) is among the hidden penny stocks to buy now. During the first quarter, Goldman Sachs Group Inc. expanded its holdings in Protalix BioTherapeutics, Inc. (NYSEAMERICAN:PLX) by a whopping 482.3%. Following the purchase of 239,751 shares, the global investment bank now owns 289,461 shares of the company’s stock, valued at approximately $741,000. […] Sep 29, 2025 - $PLX
3 Penny Stocks With Market Caps Over $30M To Consider
As the Nasdaq and S&P 500 reach record highs, investors are keenly watching the Federal Reserve's upcoming interest rate decision, which could influence market dynamics. Penny stocks may be a throwback term, but the opportunities they represent are far from old news. Typically referring to smaller or newer companies, these stocks present an underappreciated chance for growth at lower price points. Sep 16, 2025 - $PLX
Protalix BioTherapeutics to Present at Investor Summit Virtual
CARMIEL, ISRAEL / ACCESS Newswire / September 11, 2025 / Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its ... Sep 11, 2025 - $PLX
Protalix BioTherapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that Dror Bashan, the Company's President and Chief Executive Officer, will present at the H.C. Wainwright 27th Annual Global Investment Conference which is being held on September 8–10, 2025 at the Lotte New York Palace Hot Sep 2, 2025 - $PLX
PLX: New CFO to Take the Reins
By John Vandermosten, CFA NYSE:PLX READ THE FULL PLX RESEARCH REPORT Second Quarter 2025 Financial and Operational Review Protalix BioTherapeutics, Inc. (NYSE:PLX) announced 2Q:25 financial and operational results in an August 14 th , 2025 press release and in its Form 10-Q filing. The reports were followed by a conference call which discussed recent achievements, clinical updates and financial Aug 15, 2025 - $PLX
Protalix BioTherapeutics Reports Second Quarter 2025 Financial and Business Results
Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the quarter ended June 30, 2025, and provided a business and clinical update. Aug 14, 2025 - $PLX
Protalix BioTherapeutics to Announce Second Quarter 2025 Financial and Business Results on August 14, 2025
Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that it will release its financial results for the quarter ended June 30, 2025 and provide a business and clinical update on August 14, 2025. Aug 7, 2025 - $PLX
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple